Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
One of the mechanisms of action of SGLT2i is increasing ketones such as β-hydroxybutyrate. The renal cyst cells in autosomal dominant polycystic kidney disease (ADPKD) seem to be metabolically inflexible. This study assessed the effect of oral dapagliflozin on the progression of total kidney volume and chronic kidney disease (CKD) in patients with ADPKD.
An Interventional prospective study included 40 patients with ADPKD/ CKD stages II-IV. Patients were randomized into two groups: 20 patients received dapagliflozin 10 mg PO once daily, and 20 control patients. The Primary outcomes was the assessment of the progression of the sizes of renal cysts and e-GFR after 1 year of using dapagliflozin.
The change in kidney volume over 12 months: the patients receiving dapagliflozin had a delayed progression of renal cysts. The change in renal volume in the dapaglflozin group versus the control group was (8.25 ± 3.16 mL) versus (34.75 ± 4.29 mL), with a p-value < 0.001. Also, the change in Height-Adjusted Kidney Volume was less in the dapagliflozin group (0.86 ± 0.32 mL/m) versus (3.80 ± 0.50 mL/m) in the control group (p < 0.001). Patients receiving dapagliflozin showed a significant preservation of serum creatinine and e-GFR over 12 months (1.29 ± 0.08 mg/dL) and (46.94 ± 4.41 mL/min/1.73 m²) versus the control group (1.4 ± 0.09 mg/dL) and (41.52 ± 1.52 mL/min/1.73 m²), p<0.001 and p<0.001, respectively. There was no significant difference between patients receiving dapagliflozin and the control group regarding Hematuria, loin pain, and Urinary tract infections (UTI), p-value >0.05. Serum creatinine was positively correlated at the 12th month in the dapagliflozin group to body weight, systolic blood pressure, albumin creatinine ratio, total kidney volume, and height-adjusted with p-value < 0.01. The multiple linear regression analysis showed that height-adjusted total kidney volume was an independent predictor of e-GFR decline in the dapagliflozin group at 12 month (p 0.021).
The use of dapagliflozin in patients with ADPKD was associated with significant delay of renal cyst progression and preservation of renal function and e-GFR, without increasing the risk of complications over 1 year.
